The investigation uncovered that Aveo's practices were contributing to a growing epidemic of opioid abuse in the region, with Nigeria alone estimated to have around four million opioid users. The Indian Food and Drug Administration has since seized the entire stock of Aveo's products and raided their Mumbai facility. The combination of tapentadol, an opioid, and carisoprodol, a muscle relaxant banned in Europe, poses severe health risks, including the potential for overdose, respiratory problems, and seizures. Unlicensed for use globally, these drugs have found popularity as cheap street substances in West African markets.

Further investigations revealed troubling interactions between undercover operatives and Aveo's management, where company officials openly discussed the harmful effects of their products while simultaneously acknowledging the high demand among young users in Nigeria. The FDA has vowed to continue rigorous inspections and legal actions against those involved in such illegal activities, emphasizing the protection of the nation's reputation and health.